Kisqali (Ribociclib Succinate) Patent Expiration, LOE Window & CMS Spending

Kisqali (Ribociclib Succinate) by Novartis: FDA Orange Book core substance LOE 2032-05-09 (last listed 2036-10-14), 0 AB generics, $1.00B 2024 CMS Part D & Medicaid spend, and 15 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNovartis
FDA Application & PathwayN209092 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2032-05-09
Last Listed Patent or Exclusivity Date2036-10-14
Orange Book Patents (*PED Extensions)24 patents (12 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$1.00B
2024 Medicare Part D Spend$775.5M
2024 Medicaid Spend$224.6M
Reported Wholesale Price Change (CA SB 17)15 WAC filings (max 26.0% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.